Literature DB >> 7750204

Phenotypic variations and differential migration of NIH:OVCAR-3 ovarian carcinoma cells isolated from athymic mice.

A L Veatch1, L F Carson, S Ramakrishnan.   

Abstract

Transplantation of the human ovarian adenocarcinoma cell line, NIH:OVCAR-3 into athymic mice produces two morphologically distinct tumor cell populations (ascites and solid tumors). In the present study, we isolated both tumor cell phenotypes and investigated their relative malignant potential. Since cytoskeletal and morphological changes correlate with metastatic phenotype, expression of the intermediate-filament protein vimentin was compared between ascites and solid tumors. Ascites tumor cells showed a less differentiated epithelial morphology and concurrently expressed higher levels of vimentin. Ascites cells were more efficient in anchorage independent growth when compared with their solid tumor counterpart. Ascites tumor cells were also highly motile compared with the solid tumor cell population (P = 0.006). Migration of ascites tumor cells was further enhanced by type IV collagen, hyaluronic acid, and chondroitin sulfate A. Solid tumor cells removed from the same animal, however, were not significantly affected by these agents. From these studies, we conclude that ovarian cancer cells present in ascites are phenotypic variants which are highly motile compared with solid tumor cells isolated from the same animal. Ascites tumor cells with increased motility may contribute to peritoneal seeding and metastasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7750204     DOI: 10.1007/BF00132204

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  Formalin is deleterious to cytoskeleton proteins: do we need to replace it by formalin-free Kryofix?

Authors:  M E Boon; L P Kok
Journal:  Eur J Morphol       Date:  1991

2.  Antibodies to intermediate filaments as a tool in tumor diagnosis.

Authors:  F C Ramaekers; J J Puts; A Kant; O Moesker; P H Jap; G P Vooijs
Journal:  Cell Biol Int Rep       Date:  1982-07

Review 3.  Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies.

Authors:  H F Dvorak; J A Nagy; A M Dvorak
Journal:  Cancer Cells       Date:  1991-03

4.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.

Authors:  E W Thompson; S Paik; N Brünner; C L Sommers; G Zugmaier; R Clarke; T B Shima; J Torri; S Donahue; M E Lippman
Journal:  J Cell Physiol       Date:  1992-03       Impact factor: 6.384

5.  Simultaneous soft agar cloning of ascites and solid tumor specimens from patients with ovarian cancer.

Authors:  K S Sridhar; T Ohnuma; T F Plasse; J F Holland
Journal:  Cancer       Date:  1988-10-15       Impact factor: 6.860

6.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Authors:  T C Hamilton; R C Young; W M McKoy; K R Grotzinger; J A Green; E W Chu; J Whang-Peng; A M Rogan; W R Green; R F Ozols
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

7.  Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA.

Authors:  A Nagafuchi; Y Shirayoshi; K Okazaki; K Yasuda; M Takeichi
Journal:  Nature       Date:  1987 Sep 24-30       Impact factor: 49.962

8.  [Factors affecting the incidence of metastasis of malignant epithelial tumors of the ovaries].

Authors:  V L Vinokurov
Journal:  Vopr Onkol       Date:  1986

9.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels.

Authors:  H F Dvorak; T M Sioussat; L F Brown; B Berse; J A Nagy; A Sotrel; E J Manseau; L Van de Water; D R Senger
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

10.  Distinct effects of two CD44 isoforms on tumor growth in vivo.

Authors:  M S Sy; Y J Guo; I Stamenkovic
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  7 in total

1.  In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.

Authors:  Susan L Deutscher; Said D Figueroa; Senthil R Kumar
Journal:  J Labelled Comp Radiopharm       Date:  2009-12-01       Impact factor: 1.921

2.  Acidic glycosaminoglycans of abdominal mucin in a case of pseudomyxoma peritonei caused by appendiceal cancer.

Authors:  T Miyashita; K Murata; E Hoshino; H Nishiya; Y Ono; I Akaoka; O Kunii
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

3.  Inhibition of tumor invasiveness by 1alpha,25-dihydroxyvitamin D3 coupled to a decline in protein kinase A activity and an increase in cytoskeletal organization.

Authors:  M R Young; Y Lozano
Journal:  Clin Exp Metastasis       Date:  1997-03       Impact factor: 5.150

4.  CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.

Authors:  Erica L Johnson; Rajesh Singh; Shailesh Singh; Crystal M Johnson-Holiday; William E Grizzle; Edward E Partridge; James W Lillard
Journal:  World J Surg Oncol       Date:  2010-07-22       Impact factor: 2.754

5.  Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.

Authors:  Linah Al-Alem; R Chase Southard; Michael W Kilgore; Thomas E Curry
Journal:  PLoS One       Date:  2011-01-21       Impact factor: 3.240

6.  All trans-retinoic acid analogs promote cancer cell apoptosis through non-genomic Crabp1 mediating ERK1/2 phosphorylation.

Authors:  Shawna D Persaud; Sung Wook Park; Mari Ishigami-Yuasa; Naoko Koyano-Nakagawa; Hiroyuki Kagechika; Li-Na Wei
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

7.  A novel tumor-immune microenvironment (TIME)-on-Chip mimics three dimensional neutrophil-tumor dynamics and neutrophil extracellular traps (NETs)-mediated collective tumor invasion.

Authors:  Vikram Surendran; Dylan Rutledge; Ramair Colmon; Arvind Chandrasekaran
Journal:  Biofabrication       Date:  2021-04-08       Impact factor: 9.954

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.